ILT17 ANTIBODY Russian patent published in 2012 - IPC C07K16/28 C12N15/09 

FIELD: medicine.

SUBSTANCE: what is described is a monoclonal antibody specifically bound with an outer domain of human ILT7, or its fragment containing its antigen-binding region. There are presented hybridomas ILT7 No.11 and ILT7 No.17 deposited under registration numbers FERM BP-10704 and FERM BP-10705 respectively, producing a monoclonal antibody which is specifically bound with the outer domain of human ILT7. What is described is an immunogen for producing the antibody bound with the outer domain of human ILT7 representing an animal cell wherein a polynucleotide coding an amino acid sequence containing the outer domain of human ILT7, and a polynucleotide coding a γ-chain of Fc-receptor are kept in the exogenic expressed form; or a fraction of its cell membrane.

EFFECT: invention enables producing the antibody showing high specificity which enables the immunological distinction between the molecules of ILT and ILT7 families, binding with the iPS and inhibiting them, treating or preventing an interferon-related disease, including in a patient with an autoimmune disease with high production of INFb.

26 cl, 13 dwg, 7 tbl, 7 ex